We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 2,337

Federal Circuit applies Alice to biotechnology in striking down Myriad method of screening claims, leaves door open for narrower method claims

  • Ropes & Gray LLP
  • -
  • USA
  • -
  • December 18 2014

On December 17, 2014, a three judge panel of the Federal Circuit issued a ruling that may significantly narrow the scope of patent eligible subject

A wolf in sheep’s clothing is your litigation settlement anti-competitive?

  • Bryan Cave LLP
  • -
  • European Union
  • -
  • December 17 2014

As we reported in July 2014, the European Commission fined pharmaceutical company Servier and several of its generic competitors for entering into so

Planning for profitable medtech

  • Phillips Ormonde Fitzpatrick
  • -
  • Australia
  • -
  • December 17 2014

Australia has a world class history of medical device innovation. From the bionic ear to ultrasound, leave-in contact lenses to spray on skin

Update: Sandoz and Celltrion decline the invitation to dance: biosimilars challenge the applicability of the BPCIA’s exchange provisions before bringing suit

  • Sheppard Mullin Richter & Hampton LLP
  • -
  • USA
  • -
  • December 16 2014

In our previous blog post of November 11, 2014, we noted that Celltrion had filed a declaratory judgment action against Kennedy Trust for

Lessons learned from first Final Written Decision in a Hatch-Waxman related inter partes review

  • Paul Hastings LLP
  • -
  • USA
  • -
  • December 16 2014

Last week, the Patent Trial and Appeal Board issued Final Written Decisions in three inter partes review proceedings upholding the patentability of

Phase III biosimilar clinical trial & infringement threat does not create justiciable case or controversy: biosimilars will require the patent dance

  • Rosenbaum IP
  • -
  • USA
  • -
  • December 15 2014

In Sandoz Inc. v. Amgen Inc., the Federal Circuit upheld the district court decision dismissing Sandoz’s declaratory judgment action for lack of

Sequenom deal may avoid Federal Circuit decision

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 15 2014

Less than a month after their case was argued at the Federal Circuit, Illumina Inc. and Sequenom Inc. have announced a deal to settle their patent

For the first time PTAB upholds validity of pharma patents

  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • -
  • USA
  • -
  • December 15 2014

On December 9, 2014, the Patent Trial and Appeal Board (“PTAB”) upheld the validity of three Supernus Pharmaceutical’s patents relating to once-daily

Federal Circuit dismisses Sandoz’s biosimilar declaratory-judgment action

  • Frommer Lawrence & Haug LLP
  • -
  • USA
  • -
  • December 11 2014

On December 5, 2014, the Federal Circuit in Sandoz Inc. v. Amgen Inc.(Docket No. 2014-1693) affirmed the dismissal of a declaratory-judgment action

Federal Circuit rules against patent declaratory judgment actions before biosimilar application is filed

  • Ropes & Gray LLP
  • -
  • USA
  • -
  • December 11 2014

On December 5, 2014, the Federal Circuit issued its opinion in Sandoz Inc. v. Amgen Inc. et al. In a unanimous panel opinion (Judges Dyk, Taranto and